EDGAR·FLOW

TEVA PHARMACEUTICAL INDUSTRIES LTD — Form 8-K

Filed November 18, 2026 · analyzed by the 8-K Agent
8-K — Neutral significance 48/100
What the filing says
Dr. Eric Hughes, Executive Vice President of Global R&D and Chief Medical Officer, is leaving Teva effective immediately after accepting an outside offer. Dr. David Gardiner, MD, Head of Innovative Medicines Clinical Development, assumes interim R&D leadership reporting to CEO Richard Francis while Teva launches a comprehensive search for a permanent successor. The company reaffirms its R&D strategy, pipeline priorities, and $6–7 billion innovative medicines revenue target by 2030 announced at R&D Day on November 11, 2026.
Why this rating

Executive departure is notable leadership change, but no financial impact disclosed. R&D strategy and $6–7B revenue target unchanged. Interim leadership in place, successor search underway. Modest risk to execution but management confidence evident.

View original filing on SEC.gov ↗ TEVA · stock on Yahoo Finance ↗

See more from November 18, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.